The first FDA-approved acne drug with a first-in-class mechanism of action in nearly 40 years launched in the United States in November 2021 after being approved in August 2020. The first-in-class ...

Please provide your email address to receive an email when new articles are posted on . Acne vulgaris may be driven by underlying systemic, immune-inflammatory pathways. Addressing those underlying ...

Please provide your email address to receive an email when new articles are posted on . A new gel for treating acne vulgaris is set to undergo FDA review with the agency’s acceptance of a new drug ...

Trifarotene plus skin care is beneficial for patients with moderate acne vulgaris (AV) and acne-induced hyperpigmentation (AIH), according to a study published online April 29 in the International ...

The dynamics of the acne vulgaris market are anticipated to change in the coming years owing to the increase in the prevalent cases of acne vulgaris, along with the expected launch of emerging ...

Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced ...

LAVAL, QC / ACCESSWIRE / January 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced the U.S. launch of CABTREO™ (clindamycin ...

In a recent study published in the journal Nutrients, researchers review existing publications to determine the role of nutrition in the development of acne vulgaris. To this end, the complex ...

Acne vulgaris remains one of the most pervasive inflammatory skin conditions worldwide, affecting not only adolescents but also adults and contributing to significant psychosocial burden. The ...